Compare Davita Inc (DVA) vs abrdn Physical Palladium Shares ETF (PALL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs abrdn Physical Palladium Shares ETF — how do they compare? Davita Inc trades at $230.26 (market cap $14.92B), while abrdn Physical Palladium Shares ETF trades at $23.52. The key difference: Davita Inc is trading nearer its 52-week high, abrdn Physical Palladium Shares ETF nearer its low. Which is the better fit depends on your goals.
| DVA | PALL | |
|---|---|---|
Market Cap | $14.92B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $235.71 | $37.18 |
52-Week Low | $103.87 | $19.96 |
Enterprise Value | $27.47B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $235.58, up 1.19% on the day, near its pivot point of $236. The stock shows a bullish technical trend with strong moving average signals, though RSI levels suggest potential overbought conditions. Fundamentally, revenue grew to $13.64B in 2025, but net income margin dipped to 5.65%. Recent earnings beat expectations in Q4 2025 and Q1 2026, while Q3 2025 missed. Analyst sentiment is mixed with a consensus price target of $231.80, slightly below the current price.
The outlook for DVA is cautiously optimistic, supported by steady revenue growth and expansion in kidney care services. Key risks include high debt levels, with debt-to-asset ratio rising to 65.55% in 2025, and margin pressure from rising costs. Investment opportunity lies in continued execution of value-based care programs and AI-driven efficiency gains, but investors should monitor debt management and regulatory changes in healthcare reimbursement.
PALL (abrdn Physical Palladium Shares ETF) trades at $22.73, down 1.47% with bearish technical signals from moving averages. The ETF faces headwinds from palladium's 47% price decline from January 2026 highs, though recent news highlights potential buying opportunities as the metal approaches technical support levels. A 1:5 stock split occurred on May 18, 2026, which adjusted share count without changing the fund's total value.
The outlook remains cautious due to weak palladium pricing and industrial demand concerns, though some analysts see value at current levels. Key risks include commodity price volatility and Federal Reserve policy impacts. Investment appeal hinges on palladium's supply-demand dynamics improving from current depressed conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About abrdn Physical Palladium Shares ETF
PALL is a physically-backed ETF that tracks the spot price of palladium. It holds physical bullion in secure vaults, offering a liquid way to invest in this precious metal primarily used in automotive catalytic converters and electronics.
Read more on PALL →
